Table 3.
Current therapeutic strategies for the treatment of cancer patients to trigger ROS-mediated cell death
| substance | target/mechanism | treatment of |
|---|---|---|
| Auranofin | TrxR inhibitor | leukemia, solid cancer, melanoma [213] |
| + BSO | inhibition of GSH biosynthesis | head and neck cancer cells, malignant B cells [215, 216] |
| + Selenocystin | lung cancer [214] | |
| MJ25 | TrxR inhibitor | melanoma [213] |
| Imexon | prooxidant, cysteine depletion | B cell non-Hodgkin lymphoma [243, 244] |
| Calmangafodipin | SOD mimetica | metastatic colorectal cancer [245] |
| Molexafin gadolinum | TrxR inhibitor, superoxide formation | glioblastoma multiform [246] |
| Arsenic trioxide | inhibitor of mitochondrial chain, GPx and TrxR | melanoma [247] |
| + GSH depletion |